We provide you with 20 years of free, institutional-grade data for BTAI stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BTAI. Explore the full financial landscape of BTAI stock.
| Reported Date | CIK | Ticker | Type |
|---|
BioXcel Therapeutics, Inc(NASDAQ:BTAI) 
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic re...
Website: http://www.bioxceltherapeutics.com
Founded: 2017
Full Time Employees: 40
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about BTAI stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.